Agilent Technologies (NYSE:A) Price Target Raised to $145.00 at Barclays

Agilent Technologies (NYSE:A) had its price target increased by Barclays from $135.00 to $145.00 in a report published on Tuesday, Benzinga reports. Barclays currently has an underweight rating on the medical research company’s stock.

Several other research firms also recently commented on A. Citigroup raised their price objective on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a buy rating in a report on Thursday, August 22nd. Bank of America raised their price target on Agilent Technologies from $140.00 to $147.00 and gave the stock a neutral rating in a report on Thursday, August 22nd. Wells Fargo & Company started coverage on Agilent Technologies in a research note on Tuesday, August 27th. They set an overweight rating and a $157.00 price objective on the stock. TD Cowen raised their target price on Agilent Technologies from $153.00 to $160.00 and gave the stock a buy rating in a research note on Thursday, August 22nd. Finally, Evercore ISI upped their price target on Agilent Technologies from $135.00 to $145.00 and gave the company an in-line rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. According to MarketBeat, Agilent Technologies currently has an average rating of Moderate Buy and an average target price of $144.36.

Agilent Technologies Price Performance

Shares of NYSE A opened at $144.58 on Tuesday. The firm has a market cap of $42.18 billion, a price-to-earnings ratio of 34.18, a price-to-earnings-growth ratio of 6.96 and a beta of 1.05. The stock has a fifty day simple moving average of $140.87 and a two-hundred day simple moving average of $138.86. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36. Agilent Technologies has a 1-year low of $96.80 and a 1-year high of $155.35.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.06. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The firm’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.43 EPS. Analysts anticipate that Agilent Technologies will post 5.24 earnings per share for the current year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st will be issued a dividend of $0.236 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date of this dividend is Tuesday, October 1st. Agilent Technologies’s dividend payout ratio is currently 22.22%.

Insider Activity at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the sale, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the transaction, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,953 shares of company stock valued at $2,013,630 over the last 90 days. 0.33% of the stock is owned by insiders.

Institutional Investors Weigh In On Agilent Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of A. Integrated Advisors Network LLC increased its stake in shares of Agilent Technologies by 5.0% in the fourth quarter. Integrated Advisors Network LLC now owns 3,868 shares of the medical research company’s stock worth $538,000 after buying an additional 184 shares during the period. Congress Asset Management Co. MA bought a new stake in Agilent Technologies in the 4th quarter worth $541,000. Nomura Holdings Inc. purchased a new position in shares of Agilent Technologies in the fourth quarter valued at about $823,000. CWM LLC raised its stake in shares of Agilent Technologies by 55.0% during the first quarter. CWM LLC now owns 11,718 shares of the medical research company’s stock valued at $1,705,000 after acquiring an additional 4,159 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Agilent Technologies by 14.3% during the first quarter. GAMMA Investing LLC now owns 1,028 shares of the medical research company’s stock worth $150,000 after purchasing an additional 129 shares during the period. Institutional investors own 87.42% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.